Ac Immune Sa (ACIU) - News Archive

In the fast-evolving landscape of pharmaceutical sciences, adaptive companies are more likely to flourish. AC Immune is one such company currently making strides in its operational strategy and product pipeline, aiming...

Headwinds and Progress: Analyzing AC Immune s Phase 1b/2 Trial Results Amidst Revenue Struggles In a landscape where biopharmaceutical companies continually strive to innovate, AC Immune SA recently reported interim saf...

: AC Immune SA, a biopharmaceutical company focused on the development of therapeutics for neurodegenerative diseases, has recently published its financial results for the third quarter of 2024. This article provides an...

Swiss-based biopharmaceutical company AC Immune is making significant strides in the fight against neurodegenerative diseases, particularly Alzheimerns disease (AD). The company recently announced the receipt of a secon...

AC Immune s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions Swiss-based biopharmaceutical company AC Immune has announced that its investigational novel imagin...

Pharmaceutical innovation is a cornerstone of advancing healthcare, particularly in addressing neurodegenerative diseases such as Alzheimer s. AC Immune, a leading biopharmaceutical company specializing in the developme...

The burgeoning field of antibody-drug conjugates (ADCs) has demonstrated transformative potential in the treatment of various diseases, including cancer and, more recently, neurodegenerative conditions. AC Immune has em...

AC Immune SA, a leading Swiss-based clinical-stage biopharmaceutical company, recently announced that its investigational Alzheimer s disease (AD) vaccine, ACI-35.030 (now JNJ-2056), has been granted Fast Track designat...

AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024Neurodegenerative diseases like Alzheimer s, Parkinson s, and Huntington s h...

In a remarkable moment for medical innovation, giants in the industry, AC Immune and Takeda, have officially etched their names onto an exclusive option and license agreement. Destined to introduce a surge of hope for A...

article for :AC Immune, a Swiss-based clinical-stage biopharmaceutical company focusing on precision medicine for neurodegenerative diseases, recently made significant announcements regarding its novel research findings...

AC Immune, a Swiss-based biopharmaceutical company, has announced that it will regain the global rights to two of its key drug candidates, Crenezumab and Semorinemab. This decision comes as part of the company s strateg...